Treatment of Influenza with Intravenous Peramivir

Thomas Glück, MD


Journal Watch. 2010;30(24) 

In This Article


Peramivir appears to be a promising new antiviral in the armamentarium against influenza and has already received FDA emergency-use authorization for the treatment of severe pandemic H1N1 influenza. Its intravenous formulation makes it particularly attractive for treating severely ill patients, but dose-finding trials have not yet been completed in this population. Animal studies indicate that multiple doses of peramivir for up to 15 days might be appropriate for such patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.